Background and Objective: Chemokine (C-C motif) ligand (CCL)2, the prototype Th2 chemokine, is secreted by tumor cells, and has growth promoting effects. Whether CCL2 protumorigenic activities will be validated, then CCL2 and its receptor CCR2 may be therapeutic targets in cancer.
Materials and Methods

Patients source for thyroid tissue
Thyroid tissues were collected from 8 ATC patients undergoing thyroidectomy, and normal thyroid tissues from 5 patients (2 during parathyroidectomy, and 3 during laryngeal intervention). The diagnosis was determined according to known laboratory, clinical and histological criteria [36, 37] . The absence of expression of thyroperoxidase (TPO), thyrotropin (TSH) receptor, sodium/iodide symporter (NIS), and thyroglobulin (Tg) was shown by immunohistochemistry.
Microdissection and DNA extraction, detection of BRAF mutation by polymerase chain reaction single strand conformation polymorphism and direct DNA sequencing were performed as previously described [38] . Informed consent to the study was obtained from all study subjects, and was approved by the local ethical committee.
ATC cell culture
ATC cell cultures were established as previously described [29, 39, 40] .
The absence of expression of TPO, TSH receptor, NIS and Tg, and a partial and focal positivity to cytokeratin were shown by immunocytochemistry. minimum detectable dose was 4.6 pg/mL. The intra-and inter-assay coefficients of variation were 4.6% and 5.7%.
Apoptosis determination-Hoechst uptake
Primary ATC cell cultures (ANA) were seeded at a concentration of 35000 cells/mL in a 96-wells plate in a final volume of 100 mL/well, and treated with PGZ (10 or 20 mmol L -1 ) for 48 h, in a humidified atmosphere (37°C, 5% CO 2 ), then stained with Hoechst 33342 [41] [42] [43] .
It was calculated the apoptosis index (ratio between apoptotic and total cells x100), and the results were evaluated by analysis of variance (ANOVA) with Newman-Keuls multiple comparisons test.
Apoptosis determination-Annexin V binding assay
Cells were seeded in Lab-tekII Chamber Slide System (Nalge Nunc International, Naperville, IL, USA), treated with 10 or 20 mmol L -1 PGZ for 48 h, and processed as previously described [41] [42] [43] .
Nuclear extracts preparation
ANA and TFC cells were seeded at a concentration of 200000 cells/mL in cell culture dishes in 10 mL and treated with IFN-γ (1000 IU/mL) and TNF-α (10 ng/mL) in the presence or absence of 10 or 20 mmol L -1 PGZ for 1 h.
Nuclear extracts (nucleosol) were obtained as previously described [41] .
Electrophoretic mobility shift assay (EMSA)
DNA binding reactions and electrophoresis were performed as previously described [41] .
Immunoblotting
ANA cells were seeded at a concentration of 200000 cells/mL in cell culture dishes in 10 mL and treated with IFN-γ (1000 IU/mL) and TNF-α (10 ng/mL) in the presence or absence of 10 or 20 mmol L -1 PGZ for 24 h.
At the end of the treatments, cells were processed as previously described [41, 44] .
Data analysis
Values are given as mean±standard deviation (SD) for normally distributed variables (in text), or 
Results
In vitro studies
In ATC cells, CCL2 was detectable basally in supernatants in all samples, higher levels were observed in preparations B, C, D, F, G and H, whilst a slight basal secretion was shown in A and E (Figure 1) . The basal level of CCL2 in ATC supernatants ranged from 104 to 16207 pg/mL, with a mean level of 6134 ± 4973 pg/mL (P < 0.05, versus controls), showing a median increase with respect to the CCL2 level in TFC (Figure 2) .
CCL2 release was induced dose-dependently by IFN-γ, only in preparations A, E, F, and H while had no effect in the other preparations (ANOVA, P < 0.05, versus basal).
TNF-α alone in ATC cells dose-dependently induced the CCL2 release in all the preparations with the exception of preparation A; the stronger effect was observed in B, C and G (ANOVA, P < 0.05, versus basal).
The combination of TNF-α and IFN-γ had a significant synergistic effect on the CCL2 secretion ( Figure   1 ) in preparation A, and showed no effect in the others (ANOVA, P < 0.05, versus IFN-γ).
Treating ATC cells with RGZ, in the presence of IFN-γ and TNF-α, CCL2 release was inhibited dosedependently (Figure 1 ) in preparations A, F and H (ANOVA, P < 0.05, versus IFN-γ+TNF-α), while no significant effects were present in the others.
Similarly, the treatment of ATC cells with PGZ, in the presence of IFN-γ and TNF-α, dose-dependently inhibited CCL2 release (Figure 1 ) in preparations A, B, F and H (ANOVA, P < 0.05, versus IFN-γ+TNF-α), while no significant effects were present in the others.
CCL2 (251 ± 241 pg/mL) was detectable in the supernatants collected from primary thyrocyte cultures.
IFN-γ dose-dependently induced the CCL2 release (CCL2: 255 ± 236, 521 ± 283, 967 ± 489, 1187 ± 563, 1389 ± 652 pg/mL; respectively, with IFN-γ 0, 500, 1000, 5000, 10000 IU/mL; ANOVA, P < 0.001).
TNF-α dose-dependently induced the CCL2 release (CCL2: 247 ± 243, 438 ± 289, 694 ± 354, 859 ± 496 pg/mL; respectively, with TNF-α 0, 1, 5, 10 ng/mL; ANOVA, P < 0.001). The combination of IFN-γ and TNF-α had a significant synergistic effect on the CCL2 secretion (ANOVA, P < 0.0001) (Figure 2) . The treatment of TFC with RGZ or PGZ, added at the time of IFN-γ and TNF-α stimulation, had no significant effect on the CCL2 release (Figure 2) .
For comparison, we have reported mean CCL2 values in TFC (5 preparations) or in ANA (8 preparations) in Table 1 . The cell counting confirmed the above mentioned results (data not shown).
The PGZ concentration necessary for IE 50 in ANA was 38 mmol L -1 .
Apoptosis index was obtained in ATC cells using the Hoechst method. The fluorescent Hoechst dye stained both control and cells treated with PGZ (10 and 20 mmol L -1 for 48 h). The percentage of apoptotic cells increased dose-dependently: 6% of the cells were apoptotic at the PGZ lower dose reaching more than 14% with PGZ 20 mmol L -1 (ANOVA, P < 0.001) ( Figure 3C) . The induced cell apoptosis was verified by Annexin V.
In order to clarify the PPARγ agonists-inhibition on CCL2 secretion, the EMSA assay was conducted to evaluate the effect of TZD on nuclear factor-kB (NF-kB) activation in the ATC cells ( Figure 4A) . As regards mitogen-activated protein kinase (MAPK) extracellular-signal-regulated kinase 1/2 (ERK1/2), we demonstrated that ERK1/2 are activated at the basal level in ATC cells, and IFN-γ+TNF-α increased its activation. PGZ (20 mmol L -1 ) inhibited the cytokines-induced ERK1/2 phosphorylation (Figure 4B) .
Three ATC presented the V600E BRAF mutation. IFN-γ and/or TNF-α stimulated chemokines secretion, RGZ and/or PGZ modulated it, and PGZ inhibited cell proliferation similarly both in ATC from tumors with V600E BRAF mutation, and from tumors without BRAF mutations (data not shown).
The proliferation of TFC cells was decreased slightly but not significantly by PGZ, while it had no effect on total protein content (data not shown). 1
In vivo studies CCL2 levels were measured in the serum of 6 ATC patients and 5 controls (813 ± 345 versus 345 ± 212, pg/mL; respectively), showing significantly increased levels in ATC patients (P < 0.01, by ANOVA). No relationship among CCL2 serum levels and the clinical presentations of the ATC patients was observed.
Discussion
Our results show that ANA produced basally CCL2, at a higher level compared to TFC. Furthermore, circulating CCL2 is increased in ATC patients. CCL2 chemokine is secreted by ATC cells, after the treatment with cytokines, with an extremely variable pattern of modulation (no effect, or inhibition, or stimulation) by TNF-α, IFN-γ or TZDs, and a variable strength of the induced effect. CCL2 was secreted basally by TFC, and responded to IFN-γ or TNF-α, alone or in combination, in agreement with the results obtained by previous studies [45] [46] [47] . However, the basal level of CCL2 in ATC supernatants was higher compared to the CCL2 level in TFC. If CCL2 may be a marker of aggressiveness remains to be established.
IFN-γ dose-dependently induced the CCL2 release only in 4/8 ATC preparations, while all TFC responded to IFN-γ. So far, it appears that progressive dedifferentiation of thyroid cells seems to increase the levels of basal CCL2 secretion while reducing its sensitivity to cytokines stimuli; this apparent discrepancy remains to be clarified.
TNF-α induced the CCL2 release in 7/8 ATC preparations, while the response was present in all TFC (in full agreement with the results obtained by other studies in TFC) [45] [46] [47] [48] .
IFN-γ/TNF-α synergism on CCL2 secretion has been shown in TFC in our study, in agreement with the results of other papers [45] [46] [47] . However, IFN-γ+TNF-α had a significant synergistic effect on the CCL2 secretion only in 1/8 ATC preparation, and showed no significant effect in the others.
Several intracellular signaling pathways have been identified that mediate the cytokines-induced CCL2 expression. Among them, NF-kB is a well-known transcription factor that mediates induction of CCL2 release in various cell types, by: a) IFN-γ [49, 50] ; b) TNF-α [51, 52] ; c) or the combination of IFN-γ+TNF-α [46, 47] .
In this study we demonstrate an increased NF-kB activation in ATC cells, after IFN-γ, or TNF-α, or IFN-γ+TNF-α stimulation, and this apparently agrees with what observed in the above mentioned studies.
However, probably other pathways are involved, too, as the NF-kB activation was present also in ATC preparations in which the IFN-γ, or TNF-α, or IFN-γ+TNF-α stimulatory effect on CCL2 was not observed.
The involvement of ERK activation in CCL2 induction by TNF-α has been shown also by other studies [53, 54] . We demonstrate that ERK1/2 are basally activated in ATC cells, and IFN-γ+TNF-α stimulated phosphorylation and activation of ERK1/2. However, also in this case, a discrepancy between ERK activation and CCL2 secretion is observed, since the ERK activation was present also in ATC preparations in which the IFN-γ+TNF-α stimulatory effect was not observed, reinforcing the hypothesis that probably other pathways are involved in the induction of CCL2 secretion in ATC.
PGZ exerted an inhibition of CCL2 release in preparations B, F and H, and a weak inhibitory effect in preparation A, while TZD had no effect in the other ATC, and in TFC. PPARγ activators have been shown to suppress CCL2 expression, via different pathways (MAPK phosphatase-1, Toll-like receptor) even in other cell types [55, 56] .
As regards the mechanism of action involved in chemokine secretion, PPARγ agonists may act differently: 1) inhibiting NF-kB [57] ; 2) increasing the phosphorylation and activation of ERK1/2 [58] .
NF-kB was activated in ATC cells at the basal level and TZDs inhibited its activation, as reported by
Marx et al. [57] . Considering the MAPKinase ERK1/2, we have shown that PPARγ agonists were able to inhibit the cytokines-induced ERK1/2 phosphorylation [58] . Our data support TZDs effect on ATC proliferation, but are not in agreement with TZDs effects on CCL2 secretion, leading to hypothesize that other pathways take part in the chemokine modulation in ATC.
Activation of PPARγ isoforms elicits both anti-neoplastic [59] and anti-inflammatory effects [36] in several types of mammalian cells. PPARγ are also expressed in human anaplastic cancer cell lines [24] , and inhibited cell proliferation by inducing apoptosis [24] . Moreover, we have recently shown the antiproliferative effect of PPARγ agonists TZD in primary cultured human anaplastic and papillary dedifferentiated thyroid cancers cells [27, 28, 37] .
Our study agrees that PPARγ agonists do not have an inhibitory effect in TFC, but report a significant antiproliferative effect in primary ATC cells. Of note, the modulation of IFN-γ-stimulated CCL2 secretion and the antiproliferative effect of PPARγ activators in ATC are not related. The discrepancy between TZDs effects on CCL2 secretion and the inhibitory role on ATC proliferation is presumably linked to the different involved pathways, as TZDs mediate growth inhibition inducing apoptosis, as previoulsy suggested by other studies [60] . could act in a paracrine or autocrine manner to promote tumor cell growth or survival. Whether protumorigenic activities of CCL2 will be validated, then CCL2 and its receptor CCR2 may be considered as therapeutic targets in cancer [32] . Further studies in larger numbers of ATC patients will be necessary to evaluate if CCL2 might be used as a marker in the follow-up of ATC patients.
On the whole, the present results first show that ANA produced basally CCL2, at a higher level compared to TFC, and that circulating CCL2 is increased in ATC patients. ATC cells produce the CCL2 chemokine, basally and stimulated by cytokines, even if with an extremely variable pattern of modulation (no effect, or inhibition, or stimulation) by IFN-γ, TNF-α or TZDs, as the strength of the induced response.
Furthermore, a discrepancy between the variable TZDs effect on CCL2 secretion and the inhibitory role on ATC proliferation has been evidenced. These different modulatory effects in various ATC preparations suggest different types of deregulation in the intracellular pathways involved in the chemokine modulation, as already described about the secretion of the CXCL10 chemokine in ATC cells in primary cultures [30] . However, this knowledge may help in discovering new targets for the treatments of ATC.
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